Cargando…

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab

Triple-negative breast cancer (TNBC) is a biologically aggressive yet heterogeneous disease that disproportionately affects younger women and women of color compared to other breast cancer subtypes. The paucity of effective targeted therapies and the prevalence of chemotherapeutic resistance in high...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bagegni, Nusayba A, Davis, Andrew A, Clifton, Katherine K, Ademuyiwa, Foluso O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064451/ https://www.ncbi.nlm.nih.gov/pubmed/35515356 http://dx.doi.org/10.2147/BCTT.S293597

Ejemplares similares

Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
por: Bagegni, Nusayba A., et al.
Publicado: (2019)

Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2013)

Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)
por: Ademuyiwa, Foluso O., et al.
Publicado: (2023)

Spotlight on pembrolizumab in the treatment of advanced melanoma
por: Rajakulendran, Thanashan, et al.
Publicado: (2015)

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer
por: Davis, Andrew A., et al.
Publicado: (2022)

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
por: Huang, Min, et al.
Publicado: (2023)

Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Roy, Sudipta, et al.
Publicado: (2021)

Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
por: Roy, Sudipta, et al.
Publicado: (2021)

Complete Response of Triple-Negative Metaplastic Carcinoma of the Breast Using Pembrolizumab
por: Ladwa, Amrita, et al.
Publicado: (2023)

Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Takahashi, Masato, et al.
Publicado: (2023)

Is breast conservation superior to mastectomy in early stage triple negative breast cancer?
por: Saifi, Omran, et al.
Publicado: (2022)

NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
por: Venturelli, Marta, et al.
Publicado: (2018)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Advances in the Management of Early-Stage Triple-Negative Breast Cancer
por: Bhardwaj, Prarthna V., et al.
Publicado: (2023)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer
por: Duan, Fangfang, et al.
Publicado: (2022)

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer
por: Nederlof, Iris, et al.
Publicado: (2023)

Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
por: Anders, Carey K, et al.
Publicado: (2022)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
por: Loi, Sherene, et al.
Publicado: (2022)

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
por: Hattori, Masaya, et al.
Publicado: (2023)

Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins
por: Wang, Junkai, et al.
Publicado: (2023)

Managing breast cancer in younger women: challenges and solutions
por: Ademuyiwa, Foluso O, et al.
Publicado: (2015)

The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer
por: Sharma, Priyanka, et al.
Publicado: (2014)

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer
por: Marhold, Maximilian, et al.
Publicado: (2023)

Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer
por: Barnell, Erica K., et al.
Publicado: (2022)

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
por: Egelston, Colt A., et al.
Publicado: (2023)

Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
por: Abuhadra, Nour, et al.
Publicado: (2022)

Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature
por: Kruse, Megan L., et al.
Publicado: (2021)

MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer
por: Kahraman, Mustafa, et al.
Publicado: (2018)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
por: de la Cruz-Merino, Luis, et al.
Publicado: (2021)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis
por: Ghafouri, Sanaz N., et al.
Publicado: (2022)

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
por: Bagegni, Nusayba, et al.
Publicado: (2017)

Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab
por: Routh, Eric D, et al.
Publicado: (2023)

All-stage targeted therapy for the brain metastasis from triple-negative breast cancer
por: Luo, Zimiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lg6ghqdh6jhgb8rpjmc223mlhl